These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35989151)

  • 41. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
    Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
    J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies.
    Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J
    J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
    Hill LG; Loera LJ; Evoy KE; Renfro ML; Torrez SB; Zagorski CM; Perez JC; Jones SM; Reveles KR
    Addiction; 2021 Jun; 116(6):1505-1511. PubMed ID: 33140519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Public health detailing to increase naloxone access in NYC pharmacies.
    Foster CL; Tuazon E; Winkelstein E; Kunins HV; Kattan JA
    J Am Pharm Assoc (2003); 2023; 63(3):885-892. PubMed ID: 36997471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
    Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
    J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
    Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
    J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
    DiPaula BA; Cooke CE; Boyle CJ; Love RC
    J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
    Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
    Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
    J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Availability of Naloxone in 2 Underserved Urban Communities in Georgia.
    Saraiya P; Hutchins SS; Crump S; Morgan J; Wilkinson T; Walker CD; Taylor B
    J Public Health Manag Pract; 2021 May-Jun 01; 27(Suppl 3):S179-S185. PubMed ID: 33785693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial.
    Gamble A; Mashburn T; Kennelty KA; Look KA; Westrick SC; Evon DM; Tudor G; Carpenter DM
    Contemp Clin Trials; 2022 Oct; 121():106920. PubMed ID: 36096283
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
    Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
    J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Piloting an opioid callback program in community pharmacies.
    Hernandez SE; Gilson AM; Gassman M; Ford JH
    J Am Pharm Assoc (2003); 2023; 63(6):1796-1802. PubMed ID: 37574197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016.
    Meyerson BE; Agley JD; Davis A; Jayawardene W; Hoss A; Shannon DJ; Ryder PT; Ritchie K; Gassman R
    Drug Alcohol Depend; 2018 Jul; 188():187-192. PubMed ID: 29778772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
    Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
    Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
    Eldridge LA; Meyerson BE; Agley J
    J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
    Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
    MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.
    Guadamuz JS; Alexander GC; Chaudhri T; Trotzky-Sirr R; Qato DM
    JAMA Netw Open; 2019 Jun; 2(6):e195388. PubMed ID: 31173125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.